Management of Cryptococcal Meningitis in HIV Patients
Author Information
Author(s): Atul K. Patel, Ketan K. Patel, Rajiv Ranjan, Shalin Shah, Jagdish K. Patel
Primary Institution: Adit Molecular Diagnostics, 'Vedanta' Institute of Medical Sciences, Navarangpura, Ahmedabad, India
Hypothesis
The study aims to determine the treatment response rate, tolerability, and outcome of patients with cryptococcal meningitis in HIV treated with amphotericin B.
Conclusion
The recommended 2-week induction treatment with Amphotericin B monotherapy for HIV patients with cryptococcal meningitis may be suboptimal for at least one-third of the patients.
Supporting Evidence
- Headache was the most common symptom, affecting 96.29% of patients.
- CSF became sterile on the 12th day of treatment in 55.55% of patients.
- One patient developed immune reconstitution inflammatory syndrome (IRIS) after starting ART.
Takeaway
This study looked at how well a medicine called Amphotericin B works for people with a serious brain infection caused by a fungus, especially those with HIV. It found that some people might need more treatment than usual to get better.
Methodology
A prospective observational study was conducted to analyze treatment response, tolerability, and outcomes in HIV patients with cryptococcal meningitis treated with amphotericin B.
Limitations
The study suggests that findings require confirmation by larger sample sizes in appropriately powered studies.
Participant Demographics
{"age":{"median":37,"range":"26-45"},"sex":{"male":23,"female":4},"CD4_count":{"median":73,"range":"8-193"}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website